BSE: 523792 | NSE: MAZDA | Engineering - Industrial Equipments | Small Cap
Past 10 year's financial track record analysis by Moneyworks4me indicates that Mazda Ltd is a good quality company.
The key valuation ratios of Mazda Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Mazda Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 18.3% | 18.2% | 13.9% | 12.1% | 14.6% | 17.4% | 16.3% | 18.2% | 20.8% | 21.3% | - |
| Value Creation Index ⓘ | 0.3 | 0.3 | 0.0 | -0.1 | 0.1 | 0.2 | 0.2 | 0.3 | 0.5 | 0.5 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 118 | 122 | 110 | 107 | 139 | 180 | 152 | 165 | 192 | 225 | 204 |
| Sales YoY Gr. | - | 3.6% | -9.5% | -2.7% | 29.1% | 29.6% | -15.2% | 8.3% | 16.1% | 17.7% | - |
| Adj EPS ⓘ | 24.7 | 26.4 | 30.6 | 17.6 | 27.6 | 40.1 | 39.4 | 51.4 | 65.7 | 75.9 | 73.7 |
| YoY Gr. | - | 7% | 15.9% | -42.6% | 56.6% | 45.4% | -1.7% | 30.5% | 28% | 15.4% | - |
| BVPS (₹) ⓘ | 213.4 | 233.7 | 277.1 | 292.9 | 315.5 | 329.2 | 368.1 | 409.6 | 464.2 | 529.9 | 542.7 |
| Adj Net Profit ⓘ | 10.5 | 11.3 | 13 | 7.5 | 11.7 | 16 | 15.8 | 20.6 | 26.3 | 30.4 | 29 |
| Cash Flow from Ops. ⓘ | 15.7 | 17.3 | 7.3 | 13.6 | -5.1 | 22.3 | 20 | 8.4 | 23.6 | 43 | - |
| Debt/CF from Ops. ⓘ | 0.2 | 0.1 | 0.3 | 0.2 | -0.4 | 0 | 0 | 0 | 0 | 0 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 7.5% | 10.2% | 13.9% | 17.7% | ||||
| Adj EPS ⓘ | 13.3% | 22.5% | 24.4% | 15.4% | ||||
| BVPSⓘ | 10.6% | 10.9% | 12.9% | 14.2% | ||||
| Share Price | 19.3% | 28.3% | 28.8% | 3.8% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 12.1 | 11.8 | 12 | 6.2 | 9.1 | 12.1 | 11.3 | 13.2 | 15.1 | 15.3 | 13.7 |
| Op. Profit Mgn % ⓘ | 14.7 | 15.3 | 12 | 13.1 | 13.5 | 14 | 15.5 | 16.7 | 19.6 | 17.7 | 16.2 |
| Net Profit Mgn % ⓘ | 8.9 | 9.2 | 11.8 | 7 | 8.5 | 8.9 | 10.3 | 12.5 | 13.8 | 13.5 | 14.4 |
| Debt to Equity ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Working Cap Days ⓘ | 170 | 156 | 165 | 172 | 174 | 165 | 174 | 162 | 169 | 137 | 131 |
| Cash Conv. Cycle ⓘ | 77 | 70 | 79 | 94 | 88 | 91 | 112 | 112 | 116 | 94 | 110 |
Sales growth is growing at healthy rate in last 3 years 13.93%
Net Profit is growing at healthy rate in last 3 years 24.44%
Return on Equity has declined versus last 3 years average to 13.70%
Sales growth is not so good in last 4 quarters at -7.04%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 73.7 | - |
| TTM Sales (₹ Cr.) | 204 | - |
| BVPS (₹.) ⓘ | 542.7 | - |
| Reserves (₹ Cr.) ⓘ | 213 | - |
| P/BV ⓘ | 2.47 | - |
| PE ⓘ | 18.18 | - |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 1087.30 / 1650.20 |
| All Time Low / High (₹) | 2.00 / 1650.20 |
| Market Cap (₹ Cr.) | 536 |
| Equity (₹ Cr.) | 4 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 57.5 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 118 | 122 | 110 | 107 | 139 | 180 | 152 | 165 | 192 | 225 |
| Operating Expenses ⓘ | 101 | 104 | 97 | 93 | 120 | 155 | 129 | 137 | 154 | 186 |
| Manufacturing Costs | 16 | 20 | 16 | 14 | 18 | 20 | 18 | 20 | 22 | 23 |
| Material Costs | 61 | 60 | 57 | 54 | 76 | 104 | 80 | 81 | 93 | 116 |
| Employee Cost | 13 | 14 | 13 | 13 | 15 | 17 | 18 | 21 | 24 | 27 |
| Other Costs ⓘ | 11 | 10 | 11 | 11 | 12 | 13 | 12 | 15 | 15 | 20 |
| Operating Profit ⓘ | 17 | 18 | 13 | 14 | 19 | 25 | 24 | 28 | 37 | 40 |
| Operating Profit Margin (%) | 14.6% | 14.7% | 11.9% | 13.0% | 13.5% | 14.0% | 15.5% | 16.7% | 19.4% | 17.6% |
| Other Income ⓘ | 1 | 2 | 5 | 4 | 3 | 2 | 2 | 3 | 2 | 7 |
| Interest ⓘ | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation ⓘ | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 2 | 3 | 4 |
| Exceptional Items ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | 16 | 17 | 15 | 14 | 19 | 22 | 22 | 28 | 36 | 42 |
| Tax ⓘ | 5 | 5 | 2 | 4 | 4 | 6 | 6 | 6 | 9 | 10 |
| Profit After Tax | 11 | 12 | 13 | 10 | 14 | 17 | 16 | 21 | 27 | 32 |
| PAT Margin (%) | 9.5% | 9.9% | 11.7% | 9.6% | 10.2% | 9.3% | 10.7% | 12.9% | 13.9% | 14.0% |
| Adjusted EPS (₹) | 26.4 | 28.3 | 30.3 | 24.2 | 33.1 | 41.6 | 40.8 | 53.0 | 66.5 | 78.7 |
| Dividend Payout Ratio (%) | 23% | 23% | 24% | 34% | 27% | 24% | 27% | 23% | 21% | 20% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 91 | 100 | 118 | 125 | 134 | 132 | 147 | 164 | 186 | 212 |
| Share Capital ⓘ | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | 4 |
| Reserves ⓘ | 87 | 95 | 114 | 120 | 130 | 128 | 143 | 160 | 182 | 208 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 3 | 2 | 2 | 3 | 2 | 1 | 0 | 0 | 0 | 0 |
| Long Term Debt | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Short Term Debt | 3 | 2 | 2 | 3 | 1 | 0 | 0 | 0 | 0 | 0 |
| Trade Payables | 12 | 13 | 11 | 14 | 23 | 19 | 12 | 16 | 18 | 14 |
| Others Liabilities ⓘ | 17 | 18 | 9 | 10 | 14 | 16 | 13 | 12 | 20 | 14 |
| Total Liabilities ⓘ | 123 | 132 | 141 | 151 | 173 | 167 | 173 | 192 | 224 | 240 |
Fixed Assets | ||||||||||
| Gross Block | 33 | 36 | 50 | 54 | 56 | 58 | 62 | 54 | 97 | 98 |
| Accumulated Depreciation | 12 | 14 | 16 | 19 | 22 | 25 | 27 | 22 | 24 | 27 |
| Net Fixed Assetsⓘ | 21 | 23 | 34 | 34 | 34 | 33 | 35 | 32 | 73 | 72 |
| CWIP ⓘ | 0 | 3 | 4 | 4 | 8 | 17 | 25 | 40 | 0 | 0 |
| Investmentsⓘ | 33 | 41 | 47 | 57 | 43 | 28 | 40 | 31 | 43 | 78 |
| Inventories | 20 | 19 | 18 | 20 | 37 | 38 | 29 | 35 | 53 | 36 |
| Trade Receivables | 22 | 23 | 23 | 25 | 30 | 33 | 32 | 42 | 37 | 33 |
| Cash Equivalents | 11 | 10 | 3 | 6 | 5 | 10 | 7 | 5 | 8 | 14 |
| Others Assetsⓘ | 16 | 14 | 12 | 5 | 16 | 8 | 5 | 8 | 10 | 8 |
| Total Assets ⓘ | 123 | 132 | 141 | 151 | 173 | 167 | 173 | 192 | 224 | 240 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 16 | 17 | 7 | 14 | -5 | 22 | 20 | 8 | 24 | 43 |
| PBT ⓘ | 16 | 17 | 15 | 14 | 19 | 22 | 22 | 28 | 36 | 42 |
| Adjustment ⓘ | 1 | 2 | -1 | 2 | 1 | 4 | 2 | 0 | 3 | 1 |
| Changes in Working Capital ⓘ | 3 | 4 | -3 | 0 | -19 | 2 | 3 | -14 | -8 | 11 |
| Tax Paid ⓘ | -5 | -5 | -3 | -3 | -5 | -6 | -7 | -5 | -7 | -11 |
| Cash Flow From Investing Activity ⓘ | -9 | -17 | -10 | -7 | 10 | 4 | -20 | -5 | -15 | -30 |
| Capex | -4 | -7 | -15 | -1 | -7 | -13 | -10 | -16 | -5 | -3 |
| Net Investments | -5 | -10 | 5 | -6 | 16 | 16 | -10 | 11 | -10 | -28 |
| Others ⓘ | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow From Financing Activityⓘ | -4 | -4 | -4 | -4 | -9 | -19 | -2 | -6 | -6 | -6 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Paid ⓘ | 0 | 0 | 0 | -1 | -1 | -1 | -1 | -1 | -1 | -1 |
| Dividend Paid ⓘ | -2 | -3 | -3 | -3 | -3 | -7 | -1 | -4 | -5 | -6 |
| Others ⓘ | -1 | -2 | 0 | 0 | -5 | -11 | 0 | -1 | 0 | 0 |
| Net Cash Flow ⓘ | 3 | -4 | -7 | 3 | -4 | 7 | -2 | -3 | 3 | 6 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 12.9 | 12.65 | 11.88 | 8.49 | 10.88 | 12.51 | 11.69 | 13.64 | 15.22 | 15.83 |
| ROCE (%) | 18.31 | 18.23 | 13.92 | 12.14 | 14.64 | 17.4 | 16.25 | 18.15 | 20.78 | 21.27 |
| Asset Turnover Ratio | 1.06 | 1.04 | 0.88 | 0.74 | 0.86 | 1.06 | 0.9 | 0.91 | 0.92 | 0.98 |
| PAT to CFO Conversion(x) | 1.45 | 1.42 | 0.54 | 1.4 | -0.36 | 1.29 | 1.25 | 0.38 | 0.89 | 1.34 | Working Capital Days |
| Receivable Days | 64 | 62 | 69 | 80 | 72 | 64 | 77 | 81 | 74 | 56 |
| Inventory Days | 64 | 53 | 56 | 64 | 75 | 77 | 80 | 70 | 83 | 72 |
| Payable Days | 80 | 77 | 76 | 84 | 89 | 74 | 70 | 62 | 67 | 51 |
Mazda Ltd. was established in 1977, as a small unit in western India with the objective of manufacturing automated valve packages. Over the years, it gradually expanded its operations and marketing, taking care to instil the highest levels of quality in all its products, with near-obsessive attention to details and customers satisfaction.
Over the years, its quest for further growth led to an equity participation and technical collaboration with market leaders Croll-Reynolds Inc., USA, in the field of vacuum systems and air pollution control equipment.
In time, the company extended into a second international collaboration with Germany-based Kauer Engineering for Turbine Bypass Valves, followed by a consolidation of its technological strengths to diversify into Evaporators and Crystallisers.
Today two decades down the road, Mazda Ltd has come long way. It has clearly established itself, in domestic and global markets, as a pioneer and leader in its chosen fields, offering the finest “in specialised, high value†products.
In its new growth phase, the company is now radically diversifying into the high-potential sunrise industry, Biotechnology in the field of carbohydrates, rare sugars and miscellaneous bio-chemicals.
Different divisions of the company:
Engineering Division
It specialises in supplying equipments to various industries like power, fertilizers, chemicals and bulk drugs industries. It also caters to the needs of refineries, sugar and food, pulp and paper and others. Mazda Limited has built a strategic alliance with Croll-Reynolds Inc. USA (C-R), who is a major shareholder in Mazda Controls. Croll-Reynolds has shared a substantial amount of technology with Mazda. At its facilities in Ahmedabad, Mazda and Croll-Reynolds work together to design, manufacture and test high quality equipments for sale to all the regions of the world.
Biochemical Division
Special Sugars- Glycals are sophisticated Chiral building blocks that can be used in chemical, enzymatic and combinatorial synthesis of natural and unnatural complex carbohydrates, oligosaccharide and glycoconjugate targets for advanced research in the pharmaceutical and biotechnology industries. Carbohydrates are key elements in various molecular signaling and recognition process at the cellular level in all living organisms. They also play central role in human immune system, and are important in the onset of illness and disease.
Product range of the company includes:
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
